Connect your AI

Nuvation Bio NUVB 2029

2029 at other companies

BlackstoneBX

$650M-27.8%

Phillips 66PSX

$1.32B+4.5%

The Travelers CompaniesTRV

$0-100%

The Travelers CompaniesTRV

$0—

Phillips 66PSX

$1.19B-2.9%

BlackstoneBX

$2.01B+119%

Other financials

Income statement

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

Market cap$2.25B+150%

Enterprise value$2.18B+154%

P/S15.7×-66.3×

Profitability

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nuvation Bio's 2029?: Nuvation Bio (NUVB) reported 2029 of $54.04M in Q4 2025.